DENGVAXIA Drug Profile

Summary for Tradename: DENGVAXIA

High Confidence Patents:	1
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for DENGVAXIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for DENGVAXIA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Inc.	DENGVAXIA	dengue tetravalent vaccine, live	For Injection	125682	8,142,795	2029-07-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for DENGVAXIA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for DENGVAXIA

Country	Patent Number	Estimated Expiration
Spain	2429130
Japan	2011527300
Taiwan	I460190
Argentina	072796
South Africa	201100107

Supplementary Protection Certificates for DENGVAXIA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
19C1039	France		PRODUCT NAME: VIRUS CHIMERIQUES FIEVRE JAUNE/ DENGUE DE SEROTYPES 1, 2, 3 ET 4 (VIVANTS, ATTENUES); REGISTRATION NO/DATE: EU/1/18/1338 20181214

Market Dynamics and Financial Trajectory of DENGVAXIA

Last updated: April 11, 2026

What is the current market landscape for DENGVAXIA?

DENGVAXIA (CYD-TDV), developed by Sanofi Pasteur, is the first dengue vaccine approved for use in endemic countries. Approved in 2015, it targets individuals aged 9-45 in areas with high dengue transmission. The vaccine's market penetration remains limited by regulatory perceptions, safety concerns, and competitive developments.

As of 2022, the global market for dengue vaccines is estimated at approximately $370 million, with DENGVAXIA accounting for roughly 65% of sales. The largest markets include the Philippines, Thailand, Brazil, and Mexico, representing high dengue burden zones.

How does the product's regulatory status influence market access?

DENGVAXIA's regulatory landscape is complex:

• Approval and Recommendations: Approved by the World Health Organization (WHO) in 2016, with broad recommendations for endemic regions.

• Safety Concerns: Post-approval data indicated increased risk of severe dengue among seronegative recipients, leading to restrictions in some countries. For example, the Philippines mandated use only among seropositive individuals after 2018.

• Market Restrictions: Several countries, including the United States, have not approved DENGVAXIA for routine vaccination, focusing its use on specific populations.

• Regulatory Uncertainty: Ongoing safety concerns have caused delays and cautious adoption in certain markets, impacting sales growth.

What are the key drivers and inhibitors of DENGVAXIA’s sales growth?

Drivers

• High Disease Burden: Dengue affects 100-400 million annually, with 70% of cases in Asia-Pacific and Latin America.

• Government Endorsements: Several governments have integrated DENGVAXIA into national immunization programs.

• Long-term Cost-Savings: Potential for reducing healthcare expenditure in endemic regions.

Inhibitors

• Safety Profile: Mixed safety data limits wider adoption, especially among seronegative populations.

• Vaccine Hesitancy: Public confidence affected by safety concerns and misinformation.

• Pricing and Access: Cost of vaccination remains prohibitive in low-income countries without subsidies.

• Competitive Challenges: Development of newer dengue vaccines, such as Takeda's TAK-003, which shows promising efficacy profiles, threaten market share.

What is the financial trajectory forecast for DENGVAXIA?

Sanofi Pasteur's reported sales figures exhibit fluctuations:

Year	DENGVAXIA Sales (USD millions)	Notes
2016	256	Initial launch in endemic countries
2018	182	Safety concerns emerged
2020	207	Gradual recovery, new markets opening
2022	245	Stabilization with expanded inputs

Forecasts suggest:

• Moderate Growth: Compound annual growth rate (CAGR) approximately 4-5% over the next five years.

• Market Ceiling: Potential plateau due to safety restrictions and competition.

• Geographic Diversification: Focus on Latin America, where regulatory constraints are less restrictive.

• Impact of New Vaccines: Introduction of competitors like TAK-003 may reduce DENGVAXIA's market share, compressing sales margins.

How do macroeconomic factors influence the market and financial outlook?

Health budgets: Countries' vaccination budgets influence vaccine procurement. Economic downturns hamper expansion, whereas international aid programs bolster access.

Public health policies: Emphasis on integrated vector control and vaccination campaigns shapes market demand. Governments with robust disease eradication programs tend to adopt DENGVAXIA more actively.

Emerging markets: Growing middle class and urbanization increase dengue exposure risk, expanding the potential market.

Major competitors and pipeline activity

• Takeda's TAK-003: Approved in India (2022), in Phase 3 trials elsewhere, with efficacy rates exceeding 80% in certain populations.

• Butantan Institute's TV003: Under development with promising early-phase data.

• Vaccine efficacy and safety: New entrants frequently demonstrate superior safety profiles and broader efficacy across all serostatus groups.

Key Takeaways

• DENGVAXIA remains the market leader in dengue vaccination but faces regulatory scrutiny and competition.
• Market growth is supported by increasing disease burden and government adoption but limited by safety concerns.
• Sales are expected to grow at a modest pace, influenced by emerging competitors and the evolving regulatory environment.
• Pricing, public acceptance, and safety data shape future trajectory.
• New vaccines in late-stage development threaten to displace DENGVAXIA in key markets.

FAQs

1. Why is DENGVAXIA not approved for use in some countries like the US?

Because safety data indicated increased risk of severe dengue among seronegative individuals, leading regulatory agencies like the FDA to caution against use without serostatus screening.

2. Will DENGVAXIA's sales decline with new vaccine approvals?

Potentially. Competitors like TAK-003 show higher efficacy and broader safety profiles, making them more attractive options in endemic and non-endemic markets.

3. What role do public health initiatives play in market expansion?

They significantly influence demand; countries with aggressive dengue control programs tend to adopt vaccination strategies more readily.

4. How does the safety profile impact the vaccine's marketability?

Safety concerns limit use to specific populations, constrain broader adoption, and slow sales growth.

5. Could pricing strategies improve DENGVAXIA's market position?

Yes, subsidized pricing, especially in low-income countries, could enhance access and augment market share, despite safety and competition barriers.

References

[1] World Health Organization. (2016). Dengue vaccine: WHO position on use. Retrieved from https://www.who.int

[2] Sanofi Pasteur. (2022). DENGVAXIA sales report. Financial statements.

[3] Takeda Pharmaceuticals. (2022). TAK-003 phase 3 trial results. Press release.

[4] U.S. Food and Drug Administration. (2021). Dengvaxia safety update. FDA medical review.